English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.01 |
| Open | 1.12 |
| 1-Year Change | -60.42% |
| Day's Range | 0.97 - 1.21 |
PetVivo Holdings, Inc. is a development-stage company. The Company is a biomedical device company focused on licensing and commercialization of medical devices and therapeutics for pets. The Company's operating subsidiary, PetVivo, Inc., (PetVivo) is engaged in the business of acquiring/in-licensing and adapting human biomedical technology and products for commercial sale in the veterinary market to treat pets and other animals suffering from arthritis and other painful affliction. As of March 31, 2015, PetVivo's pipeline included 17 therapeutic devices for both veterinary and human clinical applications. PetVivo's pipeline includes VD-01, VD-02 and VD-06, which are indicated for osteoarthritis, and VD-04, which is indicated for urinary incontinence, among others. Its subsidiary also includes Gel-Del Technologies, Inc., which has completed a pivotal clinical trial using their thermoplastic biomaterial as a dermal filler for human cosmetic applications.
BRIEF: For the nine months ended 31 December 2021, PetVivo Holdings Inc revenues increased from $7K to $60K. Net loss increased 1% to $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and Administrative increase of 59% to $2.3M (expense), Sales and Marketing increase from $107K to $690K (expense).
Common Stock $0.001 Par, Shares auth. and o/s after the offering: 200M auth, 114,150,000 issd. Insider own approx. 1% (after the IPO). IPO:TBA.. 09/14, 1-for-500 Reverse stock split.
